Ocular Therapeutix Engages in Key Scientific Conferences Ahead
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a prominent biopharmaceutical company focused on transforming the retina therapy landscape, recently announced its participation in several important scientific conferences scheduled in the near future.
Highlighting the OIS Retina Innovation Summit
The 8th Annual OIS Retina Innovation Summit, set to take place in Long Beach, will feature Ocular Therapeutix as a key participant. This summit aims to spotlight innovations in drug delivery, an essential focus for the company.
Company Presentations
Sanjay Nayak, MBBS, PhD, who serves as the Chief Strategy Officer, will lead a presentation during the session dedicated to drug delivery. This engaging session is scheduled for Tuesday, providing valuable insights into the latest advancements in retinal therapies.
Panel Discussion
Also participating will be Chief Development Officer Peter K. Kaiser, MD. He will partake in the panel titled "Spotlight on Drug Delivery," shedding light on Ocular Therapeutix's commitment to improving treatment outcomes for retinal conditions.
Key Insights from the ASRS Annual Meeting
Continuing its engagement in key scientific dialogues, Ocular Therapeutix will also contribute to the 43rd Annual Scientific Meeting of the American Society of Retinal Specialists. This event is a platform for sharing groundbreaking research and developments in retinal treatments.
Scientific Presentations
Katherine Talcott, MD, will present a significant study on the assessment of retinal leakage in diabetic retinopathy, titled "Longitudinal Quantitative Ultra-Widefield Retinal Leakage Assessment in Diabetic Retinopathy Following a Single Axitinib Hydrogel (OTX-TKI) in the HELIOS Trial." Scheduled for Thursday, this presentation aims to uncover vital metrics that can influence ongoing treatment strategies.
Poster Presentations on Diabetic Retinopathy
Further, Devesh Kumar, MD, will present his research titled "Macular Volumetric Fluid Outcomes Following Treatment with Intravitreal Axitinib Hydrogel (OTX-TKI) in Non-Proliferative Diabetic Retinopathy" during the poster session. This poster session allows for insightful discussions and networking on advancements in the area.
Women in Ophthalmology Conference Participation
Ocular Therapeutix will also be at the Women in Ophthalmology Conference in Amelia Island, where it will present its research. This forum encourages the exchange of ideas and the sharing of female leadership in the field.
Posters on Treatment Efficacy
Diana Do, MD, will showcase her findings on "Macular Fluid Volume and Retinal Vascular Leakage Analysis Following a Single Axitinib Intravitreal Hydrogel in Diabetic Retinopathy." The dual poster presentations are designed to reach a broad audience, and they reflect Ocular's dedication to understanding and improving retinal health.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. stands at the forefront of biopharmaceutical innovation, emphasizing the enhancement of the retinal experience through its research and development initiatives. Among its key products, AXPAXLI™ (OTX-TKI) is currently in Phase 3 clinical trials aimed at combating wet age-related macular degeneration (wet AMD). This investigational treatment, based on a unique bioresorbable hydrogel formulation, represents a significant potential advancement in the management of retinal diseases.
Moreover, the company’s pipeline features DEXTENZA, an FDA-approved corticosteroid used in treating ocular inflammation following surgery, exemplifying its focus on addressing diverse ocular needs. Their investigational candidate, OTX-TIC, is also showing promise, being evaluated in a Phase 2 clinical trial for open-angle glaucoma or ocular hypertension.
Ocular Therapeutix is dedicated to reshaping the landscape of ocular therapeutics, ensuring patients receive breakthrough solutions that enhance their quality of life.
Contact Information
For further inquiries, Ocular Therapeutix, Inc. can be reached through their Vice President of Investor Relations, Bill Slattery, at bslattery@ocutx.com.
Frequently Asked Questions
What is Ocular Therapeutix known for?
Ocular Therapeutix, Inc. is known for developing innovative biopharmaceutical therapies aimed at treating retinal diseases and enhancing ocular health.
What conferences is Ocular Therapeutix participating in?
Ocular Therapeutix is participating in the OIS Retina Innovation Summit and the American Society of Retinal Specialists Annual Meeting, among others.
What is AXPAXLI?
AXPAXLI™ (also OTX-TKI) is Ocular Therapeutix's investigational drug for retinal diseases, currently undergoing Phase 3 trials for wet AMD.
How does DEXTENZA work?
DEXTENZA is an FDA-approved corticosteroid that helps manage ocular inflammation and pain following ophthalmic surgery.
Who can be contacted for investor inquiries?
Bill Slattery, the Vice President of Investor Relations at Ocular Therapeutix, can be contacted for inquiries related to investments.
